273 related articles for article (PubMed ID: 31119266)
1. Oral anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1: a current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke.
Sulzgruber P; Wassmann S; Semb AG; Doehner W; Widimsky P; Gremmel T; Kaski JC; Savarese G; Rosano GMC; Borghi C; Kjeldsen K; Torp-Pedersen C; Schmidt TA; Lewis BS; Drexel H; Tamargo J; Atar D; Agewall S; Niessner A
Eur Heart J Cardiovasc Pharmacother; 2019 Jul; 5(3):171-180. PubMed ID: 31119266
[TBL] [Abstract][Full Text] [Related]
2. Ischemic stroke risk estimation in patients without oral anticoagulation: an observational cohort study based on secondary data from Germany.
Wicke FS; Schaller MA; Karymova K; Beyer M; Müller BS
BMC Cardiovasc Disord; 2019 Apr; 19(1):94. PubMed ID: 31014253
[TBL] [Abstract][Full Text] [Related]
3. Stroke and bleeding risk scores in patients with atrial fibrillation and valvular heart disease: evaluating 'valvular heart disease' in a nationwide cohort study.
Lip GYH; Jensen M; Melgaard L; Skjøth F; Nielsen PB; Larsen TB
Europace; 2019 Jan; 21(1):33-40. PubMed ID: 29986001
[TBL] [Abstract][Full Text] [Related]
4. Contemporary Trends in Oral Anticoagulant Prescription in Atrial Fibrillation Patients at Low to Moderate Risk of Stroke After Guideline-Recommended Change in Use of the CHADS
Katz DF; Maddox TM; Turakhia M; Gehi A; O'Brien EC; Lubitz SA; Turchin A; Doros G; Lei L; Varosy P; Marzec L; Hsu JC
Circ Cardiovasc Qual Outcomes; 2017 May; 10(5):. PubMed ID: 28506981
[TBL] [Abstract][Full Text] [Related]
5. Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: a joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE).
Lip GYH; Collet JP; Caterina R; Fauchier L; Lane DA; Larsen TB; Marin F; Morais J; Narasimhan C; Olshansky B; Pierard L; Potpara T; Sarrafzadegan N; Sliwa K; Varela G; Vilahur G; Weiss T; Boriani G; Rocca B;
Europace; 2017 Nov; 19(11):1757-1758. PubMed ID: 29096024
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness and safety of rivaroxaban vs. warfarin in non-valvular atrial fibrillation patients with a non-sex-related CHA2DS2-VASc score of 1.
Coleman CI; Turpie AGG; Bunz TJ; Eriksson D; Sood NA; Baker WL
Eur Heart J Cardiovasc Pharmacother; 2019 Apr; 5(2):64-69. PubMed ID: 30020424
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Adherence to Guideline-Directed Antithrombotic Therapy for Atrial Fibrillation at Hospital Discharge.
Dupree L; DeLosSantos M; Smotherman C
J Cardiovasc Pharmacol Ther; 2018 Nov; 23(6):502-508. PubMed ID: 29806486
[TBL] [Abstract][Full Text] [Related]
8. Net clinical benefit of warfarin in individuals with atrial fibrillation across stroke risk and across primary and secondary care.
Allan V; Banerjee A; Shah AD; Patel R; Denaxas S; Casas JP; Hemingway H
Heart; 2017 Feb; 103(3):210-218. PubMed ID: 27580623
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of Patients With Atrial Fibrillation Newly Recommended for Oral Anticoagulation Under the 2014 American Heart Association/American College of Cardiology/Heart Rhythm Society Guideline.
Gray MP; Saba S; Zhang Y; Hernandez I
J Am Heart Assoc; 2018 Jan; 7(1):. PubMed ID: 29301756
[TBL] [Abstract][Full Text] [Related]
10. Impact of the CHA2DS2-VASc score on anticoagulation recommendations for atrial fibrillation.
Mason PK; Lake DE; DiMarco JP; Ferguson JD; Mangrum JM; Bilchick K; Moorman LP; Moorman JR
Am J Med; 2012 Jun; 125(6):603.e1-6. PubMed ID: 22502952
[TBL] [Abstract][Full Text] [Related]
11. Risk profiles and pattern of antithrombotic use in patients with non-valvular atrial fibrillation in Thailand: a multicenter study.
Krittayaphong R; Winijkul A; Methavigul K; Wongtheptien W; Wongvipaporn C; Wisaratapong T; Kunjara-Na-Ayudhya R; Boonyaratvej S; Komoltri C; Kaewcomdee P; Yindeengam A; Sritara P;
BMC Cardiovasc Disord; 2018 Aug; 18(1):174. PubMed ID: 30144802
[TBL] [Abstract][Full Text] [Related]
12. Meta-analysis of CHADS2 versus CHA2DS2-VASc for predicting stroke and thromboembolism in atrial fibrillation patients independent of anticoagulation.
Zhu WG; Xiong QM; Hong K
Tex Heart Inst J; 2015 Feb; 42(1):6-15. PubMed ID: 25873792
[TBL] [Abstract][Full Text] [Related]
13. Stroke risk reduction with oral anticoagulation using CHA2DS2-VASc in a Japanese AF population: A modeling analysis.
Senoo K; Lane DA; Lip GY
Int J Cardiol; 2015 Feb; 181():247-54. PubMed ID: 25528530
[TBL] [Abstract][Full Text] [Related]
14. Anticoagulation Status and Left Atrial Appendage Occlusion Indications in Hospitalized Cardiology Patients with Atrial Fibrillation: A Hellenic Cardiorenal Morbidity Snapshot (HECMOS) Sub-Study.
Tsiachris D; Papakonstantinou PE; Doundoulakis I; Tsioufis P; Botis M; Dimitriadis K; Leontsinis I; Kordalis A; Antoniou CK; Mantzouranis E; Iliakis P; Vlachakis PK; Gatzoulis KA; Tsioufis K
Medicina (Kaunas); 2023 Oct; 59(10):. PubMed ID: 37893599
[No Abstract] [Full Text] [Related]
15. Effectiveness of CHA
van Doorn S; Rutten FH; O'Flynn CM; Oudega R; Hoes AW; Moons KGM; Geersing GJ
Int J Cardiol; 2018 Dec; 273():123-129. PubMed ID: 30224261
[TBL] [Abstract][Full Text] [Related]
16. Patients with atrial fibrillation and mid-range ejection fraction differ in anticoagulation pattern, thrombotic and mortality risk independently of CHA
Jurin I; Lucijanic M; Jurin H; Starcevic B; Varvodic J; Catic J; Jurisic A; Vitlov P; Sokol Tomic S; Lucijanic J; Hadzibegovic I
Heart Vessels; 2020 Sep; 35(9):1243-1249. PubMed ID: 32248252
[TBL] [Abstract][Full Text] [Related]
17. Oral anticoagulation, aspirin, or no therapy in patients with nonvalvular AF with 0 or 1 stroke risk factor based on the CHA2DS2-VASc score.
Lip GY; Skjøth F; Rasmussen LH; Larsen TB
J Am Coll Cardiol; 2015 Apr; 65(14):1385-94. PubMed ID: 25770314
[TBL] [Abstract][Full Text] [Related]
18. Recommendations on stroke prevention for patients having a CHA
Chao TF; Chen SA; Lip GYH
Trends Cardiovasc Med; 2019 Oct; 29(7):427-428. PubMed ID: 30833072
[No Abstract] [Full Text] [Related]
19. CHA2DS2-VASc score and fibrinogen concentration in patients with atrial fibrillation.
Semczuk-Kaczmarek K; Płatek AE; Ryś A; Adamowicz J; Legosz P; Kotkowski M; Dudzik-Płocica A; Gorko D; Szymański FM; Filipiak KJ
Adv Clin Exp Med; 2019 Nov; 28(11):1451-1457. PubMed ID: 31596555
[TBL] [Abstract][Full Text] [Related]
20. CHA
Kim TH; Yang PS; Kim D; Yu HT; Uhm JS; Kim JY; Pak HN; Lee MH; Joung B; Lip GYH
Stroke; 2017 Nov; 48(11):2984-2990. PubMed ID: 28939672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
